⚠ Evidence warning: Clinical trials or other evidence do not support the claim that DL-phenylalanine relieves chronic pain in 50 to 75 percent of patients (and 40 to 50 percent in fibromyalgia, 25 to 30 percent in neuropathic pain) without tolerance or dependence. This page keeps it as a report of what people, websites or other media say.

Phenylalanine for Pain Management

Pain Management — scientific infographic poster

D-phenylalanine is one of the few synthetic D-amino acids with a documented and mechanistically clear clinical action in humans. Unlike the L-form, which feeds into protein synthesis and the catecholamine cascade, the D-form is metabolically inert for those purposes — the body's enzymes are stereospecific for L-amino acids and cannot use D-phenylalanine for either function. What the D-form does do is bind to and inhibit enkephalinase, the carboxypeptidase enzyme that degrades the endogenous pentapeptide opioids met-enkephalin and leu-enkephalin. By prolonging the synaptic half-life of the body's own opioids, D-phenylalanine amplifies endogenous opioid analgesia without producing tolerance, dependence, respiratory depression, or any of the other liabilities of exogenous opioid drugs. This mechanism, proposed by Ehrenpreis in papers from 1982 and 1985 and tested in only a few small human studies (the one placebo-controlled trial found, from 1986, reported no significant pain relief over placebo), makes D-phenylalanine (usually delivered as the racemic mixture DLPA) one of the most distinctive nutritional approaches to chronic pain.


Table of Contents

  1. The Endogenous Opioid System
  2. Enkephalinase — The Pain Pathway's Off-Switch
  3. D-Phenylalanine as Enkephalinase Inhibitor
  4. Why Only the D-Form Works for Pain
  5. The Ehrenpreis Pioneering Trials
  6. Human Trials of D-Phenylalanine for Chronic Pain
  7. Chronic Low Back Pain
  8. Osteoarthritis and Joint Pain
  9. Headache, Migraine, and TMJ Pain
  10. Fibromyalgia and Centralized Pain
  11. Neuropathic Pain Considerations
  12. Dosing, Titration, and the Two-to-Four Week Window
  13. Comparison to Alpha-Lipoic Acid-Supplemented Protocols
  14. Cautions, Contraindications, and PKU
  15. Key Research Papers
  16. Connections
  17. Featured Videos

The Endogenous Opioid System

The endogenous opioid system is the body's intrinsic analgesic and emotional-regulation network. It comprises three families of opioid peptides — the endorphins, the enkephalins, and the dynorphins — that bind to three families of opioid receptors (mu, delta, and kappa) distributed throughout the brain, spinal cord, peripheral nerves, gut, and immune cells.

The three peptide families have different precursor proteins and different anatomic distributions:

Of the three families, the enkephalins are most relevant to the D-phenylalanine mechanism. They are released continuously at the dorsal horn of the spinal cord and at multiple supraspinal sites to provide a baseline analgesic tone — the reason that ordinary minor injuries do not produce intolerable pain. Loss of enkephalin tone is implicated in chronic pain states where the central nervous system loses the ability to modulate incoming pain signals appropriately.

Back to Table of Contents

Enkephalinase — The Pain Pathway's Off-Switch

The enkephalin pentapeptides have a half-life of seconds in the synaptic cleft — far shorter than would be useful for sustained analgesic signaling. The brevity is enforced by two metallopeptidase enzymes, neutral endopeptidase (neprilysin) and aminopeptidase N, each of which inactivates the peptide:

Together these two enzymes ensure that enkephalin signaling at the synapse is intense but transient. Pharmacologic inhibition of either enzyme prolongs enkephalin signaling and produces measurable analgesia. The drug development field has spent decades trying to produce orally active, brain-penetrant enkephalinase inhibitors. Compounds like racecadotril (an enkephalinase inhibitor used for diarrhea), thiorphan, and various dual NEP/APN inhibitors are pharmacologic tools in this space. None have achieved widespread clinical use as analgesics, partly because of poor brain penetration of the more potent compounds and partly because of competing interest in the same enzymes for blood pressure regulation (NEP also degrades natriuretic peptides — the basis for the heart-failure drug sacubitril).

Drug researchers have kept pursuing the same idea with “dual enkephalinase inhibitors” that block both enkephalin-destroying enzymes at once. A 2007 review describes the finding that enkephalins are inactivated by neutral endopeptidase and aminopeptidase N, which synthetic dual inhibitors can block, as a promising way to develop “physiological” painkillers devoid of morphine side effects. A 2012 review reports that raising enkephalin levels by blocking both enzymes has painkilling effects in various animal models of inflammatory and neuropathic pain, and that dual enkephalinase inhibitors were then in early-stage clinical trials.

D-phenylalanine occupies an interesting niche in this landscape: it is a weak but orally bioavailable enkephalinase inhibitor that does cross the blood-brain barrier (because the L-type amino acid transporter 1 (LAT1) does not discriminate stereochemistry as strongly as the metabolic enzymes do), and it has been used clinically for decades with a benign safety profile. The therapeutic effect builds slowly — weeks rather than hours — but the cumulative enkephalin tonic enhancement produces real analgesia in a meaningful subset of patients.

Back to Table of Contents

D-Phenylalanine as Enkephalinase Inhibitor

The enkephalin pentapeptides have the sequence Tyr-Gly-Gly-Phe-Met (met-enkephalin) or Tyr-Gly-Gly-Phe-Leu (leu-enkephalin). Neutral endopeptidase cleaves between the glycine in position 3 and the phenylalanine in position 4; aminopeptidase N removes the tyrosine in position 1. The substrate-recognition pocket of NEP has a particular affinity for the phenylalanine residue.

D-phenylalanine acts as a competitive substrate analog. It occupies the active site of NEP but is not efficiently cleaved (because the enzyme is also somewhat stereospecific for the L-form of the substrate phenylalanine residue, although less so than the catecholamine synthesis enzymes). The result is that D-phenylalanine binds to the enzyme, slows its turnover on its actual physiologic substrate (the enkephalin pentapeptides), and thereby prolongs enkephalin half-life in the synapse.

The effect is concentration-dependent but modest in magnitude — D-phenylalanine is not a strong inhibitor. The pharmacologic profile is more like a slow, sustained increase in tonic enkephalin signaling than a punctate analgesic event. This explains both the clinical pattern (gradual onset over 1 to 4 weeks, cumulative effect) and the safety profile (no acute respiratory depression, no euphoria, no addiction potential, no tolerance with chronic use).

A secondary mechanism that may contribute: D-phenylalanine can be converted in small amounts to phenylethylamine (PEA) through the same trace-amine pathway that uses L-phenylalanine, and PEA has its own modest analgesic and mood-elevating effects. The relative contribution of the PEA pathway versus the direct enkephalinase inhibition is debated.

Back to Table of Contents

Why Only the D-Form Works for Pain

The L-form of phenylalanine does not inhibit enkephalinase. It is the physiologic substrate for the body's transaminase, hydroxylase, and decarboxylase enzymes and is rapidly metabolized through those routes before it can accumulate at concentrations that would affect enkephalinase. The D-form, by contrast, is not a good substrate for any of those L-stereospecific metabolic enzymes, so it remains available in plasma and at peripheral and central nervous system sites for the comparatively slow enkephalinase interaction.

The three commercially available forms produce different effects for pain:

The fact that DLPA contains half the D-form per gram of pure DPA means dosing is roughly doubled to achieve the same enkephalinase effect — 2,000 mg DLPA delivers roughly 1,000 mg of D-phenylalanine plus 1,000 mg of L-phenylalanine. For most patients this is the right balance, but patients who have already optimized their catecholamine status through tyrosine or L-phenylalanine alone and want the pure analgesic effect may prefer DPA alone.

Back to Table of Contents

The Ehrenpreis Pioneering Trials

Seymour Ehrenpreis at the Chicago Medical School was the principal pioneer of the D-phenylalanine / enkephalinase hypothesis. His 1982 paper in Substance and Alcohol Actions/Misuse proposed that D-phenylalanine could produce analgesia by inhibiting the carboxypeptidases that degrade enkephalins. The proposal was based on enzyme kinetics work showing that D-amino acid analogs of the natural enkephalin scissile bond could competitively inhibit the relevant carboxypeptidases.

In a 1985 review of animal and human studies, Ehrenpreis reported that D-phenylalanine, bacitracin and puromycin produce long-lasting, naloxone-reversible pain relief in mice, that D-phenylalanine potentiates acupuncture analgesia in mice and humans, and that it had been used to ease a variety of human chronic pain conditions.

The Ehrenpreis work was followed by mechanistic confirmation studies in animal models. Several groups demonstrated that D-phenylalanine pretreatment potentiated morphine analgesia and prolonged the analgesic effect of acupuncture in rats — both findings consistent with enkephalinase inhibition increasing endogenous opioid tone. A Japanese group (Kitade, Hyodo and colleagues) published papers in 1981, 1988 and 1990 on this acupuncture-potentiation effect in people; their 1981 preliminary study in 3 volunteers found that D-phenylalanine extended the analgesic effect of acupuncture in all 3.

In the group’s 1990 report, 30 patients with chronic low back pain were given acupuncture 30 minutes after taking 4.0 grams of D-phenylalanine by mouth; compared with a placebo group, the effect was 26% greater, a difference that was not statistically significant. In 56 tooth extractions done under acupuncture anaesthesia, 18 patients had taken 4.0 grams of D-phenylalanine 30 minutes earlier; compared with the 38 placebo cases, the effect was significantly greater, by 35% (P < 0.01).

Back to Table of Contents

Human Trials of D-Phenylalanine for Chronic Pain

The human evidence for D-phenylalanine in chronic pain comes from a few small studies. The report of the 1986 trial below notes that earlier, preliminary studies of chronic pain patients had shown response rates to D-phenylalanine of 32% to 75%.

Walsh and colleagues in 1986 ran a double-blind crossover trial in 30 people with chronic pain from varied causes that had not been relieved by multiple treatments. Each took D-phenylalanine 250 mg or a lactose placebo by mouth four times a day for four weeks, then switched to the other for four more weeks. More pain relief on D-phenylalanine was reported by 25% of the patients, more pain relief on placebo by 22%, and no difference by 53%. The authors concluded that there appears to be no significant analgesic effect from D-phenylalanine in chronic pain patients when compared to placebo.

A 1981 French series with no control group gave D-phenylalanine 250 mg three times a day (15 days on, a 10-day pause, then resumed) to 9 terminally ill cancer patients with severe incident pain. Seven of the 9 were relieved and did not ask for more or other painkillers until they died, and no side effect was reported.

Practitioners who use DLPA report that approximately 50 to 75 percent of patients with chronic pain experience meaningful pain reduction with DLPA at 750 to 2,000 mg per day over 2 to 8 weeks. The response is gradual, partial rather than complete, and most pronounced in patients with somatic nociceptive pain (joint, low back, postoperative) and less reliable for purely neuropathic pain.

Back to Table of Contents

Chronic Low Back Pain

Chronic low back pain is the most common chronic pain condition in adults and the most frequent indication for DLPA in clinical practice. The pain typically combines mechanical components (disc, facet joint, sacroiliac joint, muscle spasm) with central sensitization in many patients with chronicity longer than 3 months.

The DLPA mechanism addresses pain through the spinal enkephalin tone rather than through any disease-modifying effect on the structural source. This means it is most effective when combined with measures that address the underlying pathology — physical therapy, postural correction, weight management, ergonomic adjustment, treatment of accompanying depression and sleep disturbance. As monotherapy in patients with active structural pathology, DLPA provides only partial relief.

A protocol practitioners describe for chronic low back pain: DLPA 750 mg twice daily for 4 weeks, with concurrent magnesium glycinate 400 mg per day, vitamin D3 to a serum level of at least 50 ng/mL, and physical therapy, reassessed at 4 weeks. With meaningful improvement the effective dose is continued; with no improvement the dose is raised to 1,000 mg twice daily for another 4 weeks before non-response is concluded.

Back to Table of Contents

Osteoarthritis and Joint Pain

Osteoarthritis is a leading cause of chronic pain and disability in adults over 50. The pain combines mechanical pain from cartilage loss and bone-on-bone contact with synovial inflammation. The enkephalin-tone mechanism of DLPA addresses the centrally amplified component of osteoarthritis pain rather than the structural cartilage damage.

DLPA is most effective in osteoarthritis when combined with:

Practitioners describe the DLPA pain effect as gradual, partial, and additive to other measures — not a replacement for surgical evaluation in advanced disease nor for joint replacement when indicated.

Back to Table of Contents

Headache, Migraine, and TMJ Pain

DLPA has been used for tension headache, chronic daily headache, and temporomandibular joint (TMJ)-associated facial pain with mixed but generally favorable results. The mechanism is the same enkephalin-tone effect rather than any specific antimigraine action.

An important caveat for migraine specifically: a subset of migraine sufferers report that catecholamine precursor loading (including phenylalanine and tyrosine) can trigger migraines, presumably through tyramine-like or PEA-mediated mechanisms. For people with established migraine, practitioners describe a small-dose trial (250 mg DLPA twice daily for 2 weeks) with a careful headache diary before the dose is raised, and stopping DLPA if migraine frequency increases.

For TMJ pain, the central enkephalin enhancement provided by DLPA can be a useful adjunct to physical therapy, occlusal splints, and stress management. The pain in TMJ disorders frequently has both peripheral (muscle, joint capsule) and central (sleep bruxism, stress) components, and the central component responds to enkephalin-tone enhancement.

Back to Table of Contents

Fibromyalgia and Centralized Pain

Fibromyalgia is the prototypical centralized pain syndrome — widespread pain in the absence of peripheral nociceptive lesions, accompanied by fatigue, non-restorative sleep, and frequent comorbid depression and anxiety. The pain mechanism is centrally amplified, with loss of descending inhibition (the system that normally damps incoming pain signals at the spinal cord) being a prominent feature.

DLPA has theoretical appeal in fibromyalgia because:

Clinical experience suggests partial benefit in approximately 40 to 50 percent of fibromyalgia patients with DLPA at 1,500 to 2,000 mg per day over 8 to 12 weeks. The response, when present, is typically modest reduction in baseline pain rather than complete relief. For more on the broader fibromyalgia approach, see our Chronic Pain page.

Back to Table of Contents

Neuropathic Pain Considerations

Neuropathic pain — pain arising from damage to the nervous system itself rather than from peripheral tissue injury — is mechanistically distinct from nociceptive pain and often responds poorly to opioid medications including the endogenous enkephalin enhancement provided by DLPA. The neuropathic pain conditions include diabetic peripheral neuropathy, post-herpetic neuralgia, post-surgical neuropathic pain, central post-stroke pain, and complex regional pain syndrome.

Practitioners who use DLPA in neuropathic pain place it as a third-line option, after first-line agents (gabapentin, pregabalin, duloxetine, amitriptyline) and after appropriate nutritional support for nerve repair (alpha-lipoic acid 600 to 1,800 mg per day, B12, methylated folate, B6 short of toxicity thresholds, acetyl-L-carnitine). Practitioners report a lower response rate in neuropathic pain than in nociceptive pain — perhaps 25 to 30 percent rather than the 50 to 75 percent they report for somatic chronic pain.

Back to Table of Contents

Dosing, Titration, and the Two-to-Four Week Window

Practitioners describe DLPA for pain as having two clinically important features: a slow onset (1 to 4 weeks to reach therapeutic effect) and a dose-response window that is meaningful but not steep. The human studies used D-phenylalanine 250 mg three times a day (the 1981 cancer-pain series) or four times a day (the 1986 placebo-controlled trial). The dosing practices practitioners describe are:

  1. Starting at therapeutic doses, not below. Practitioners report that a trial at 250 mg per day will likely produce no effect even in a responder, and describe starting at 750 mg per day divided into two doses.
  2. Allowing 2 to 4 weeks before concluding non-response. The enkephalin tonic effect is described as building gradually, and practitioners name premature discontinuation as the most common reason for apparent failure.
  3. Raising the dose only when needed. Where 750 mg per day produces a partial response at 4 weeks, practitioners describe increasing to 1,500 mg per day for another 4 weeks. They give 2,000 mg per day as the maximum for self-directed use, with higher doses taken under a clinician.
  4. Taking it on an empty stomach. Large neutral amino acids (LNAAs) compete with phenylalanine for the LAT1 transporter at the blood-brain barrier. Taking DLPA 30 minutes before meals or 90 minutes after meals is described as maximizing brain delivery.
  5. Morning and early-afternoon timing. The L-component catecholamine boost can interfere with sleep, so practitioners describe morning and early-afternoon doses rather than evening doses.

A titration schedule practitioners describe:

Back to Table of Contents

Comparison to Alpha-Lipoic Acid-Supplemented Protocols

For neuropathic pain specifically, alpha-lipoic acid (ALA) at 600 to 1,800 mg per day has substantially better evidence than DLPA. The German ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) trial and the SYDNEY trial found that alpha-lipoic acid at 600 mg intravenous (IV) daily for about three weeks improves symptoms, including pain, in diabetic neuropathy (in SYDNEY, after 14 treatments, the symptom score improved by an average of 5.7 points on alpha-lipoic acid versus 1.8 points on placebo, with significant improvement in one attribute of nerve conduction), with maintenance at 600 to 1,200 mg oral daily showing benefit in follow-up trials.

For nociceptive pain, alpha-lipoic acid is less directly analgesic but can be combined with DLPA for an additive effect:

Other adjuncts practitioners combine with DLPA for chronic pain: magnesium glycinate (300 to 400 mg per day for N-methyl-D-aspartate (NMDA) receptor modulation), vitamin D3 (to 50 to 80 ng/mL serum 25-hydroxyvitamin D (25-OH-D)), omega-3 fatty acids (2 to 4 g eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) per day for anti-inflammatory effect), and low-dose naltrexone (4.5 mg per day, prescription, for the paradoxical opioid-tone-enhancement effect that complements the enkephalinase mechanism).

Back to Table of Contents

Cautions, Contraindications, and PKU

Back to Table of Contents

Key Research Papers

  1. Ehrenpreis S (1982). D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application. Subst Alcohol Actions Misuse 3(4):231-9. — PubMed PMID: 6301083
  2. Ehrenpreis S (1985). Analgesic properties of enkephalinase inhibitors: animal and human studies. Prog Clin Biol Res 192:363-70. — PubMed PMID: 2934746
  3. Russell AL, McCarty MF (2000). DL-phenylalanine markedly potentiates opiate analgesia - an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. Med Hypotheses 55(4):283-8. — PubMed PMID: 10998643
  4. Walsh NE, Ramamurthy S, Schoenfeld L, Hoffman J (1986). Analgesic effectiveness of D-phenylalanine in chronic pain patients. Arch Phys Med Rehabil 67(7):436-9. — PubMed PMID: 3524509
  5. Donzelle G et al. (1981). Curing trial of complicated oncologic pain by D-phenylalanine. Anesthesie Analgesie Reanimation. — PubMed PMID: 7114516
  6. Kitade T, Minamikawa M, Nawata T, Shinohara S, Hyodo M, Hosoya E (1981). An experimental study on the enhancing effects of phenylalanine on acupuncture analgesia. Am J Chin Med 9(3):243-8. — PubMed PMID: 7053024
  7. Kitade T, Odahara Y, Shinohara S, Ikeuchi T, Sakai T, Morikawa K, Minamikawa M, Toyota S, Kawachi A, Hyodo M (1990). Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia by D-phenylalanine (2nd report)--schedule of administration and clinical effects in low back pain and tooth extraction. Acupunct Electrother Res 15(2):121-35. — PubMed PMID: 1978503
  8. Cheng RS, Pomeranz B (1979). Electroacupuncture analgesia could be mediated by at least two pain-relieving mechanisms: Endorphin and non-endorphin systems. Life Sciences. — PubMed PMID: 160969
  9. Roques BP et al. (1980). The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice. Nature. — PubMed PMID: 7001254
  10. Roques BP, Noble F (1995). Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase and aminopeptidase N) as potential new medications. NIDA Research Monograph. — PubMed PMID: 8742783
  11. Noble F, Roques BP (2007). Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. Expert Opin Ther Targets 11(2):145-59. — PubMed PMID: 17227231
  12. Roques BP, Fournié-Zaluski MC, Wurm M (2012). Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov 11(4):292-310. — PubMed PMID: 22460123
  13. Farthing MJ (2006). Antisecretory drugs for diarrheal disease. Dig Dis 24(1-2):47-58. — PubMed PMID: 16699263
  14. Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA (1995). Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38(12):1425-33. — PubMed PMID: 8786016
  15. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D; SYDNEY Trial Study Group (2003). The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care 26(3):770-6. — PubMed PMID: 12610036

PubMed Topic Searches

  1. PubMed: D-phenylalanine enkephalinase analgesia
  2. PubMed: DLPA chronic pain
  3. PubMed: Neutral endopeptidase enkephalin pain
  4. PubMed: Endogenous opioid enhancement
  5. PubMed: Phenylalanine osteoarthritis

Back to Table of Contents

Connections

Back to Table of Contents